ArticleThe journals of gerontology. Series A, Biological sciences and medical sciences2025
Identifying motor resilience proteins associated with motor decline in older adults.
Article in The journals of gerontology. Series A, Biological sciences and medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundThis study will identify cortical proteins that may provide motor resilience, the capacity to maintain motor function despite underlying Alzheimer's disease and related dementias (ADRD) pathologies.
methodsWe studied 850 decedents with postmortem indices of 10 ADRD pathologies and proteome from dorsal lateral prefrontal cortex. Annual parkinsonian signs were assessed using a modified Unified Parkinson Disease Rating Scale. First, we adjusted linear models for ADRD pathologies to isolate resilience proteins, unrelated to ADRD pathologies, but that were related to linear motor decline. Next, functional mixed effects (FMEs) models were used to determine if resilience proteins were related to non-linear motor decline. Exploratory functional enrichment was then used to assess pathways underlying motor resilience proteins.
resultsMean age at death was 90 years (SD = 6.4), 69% female and 7 years follow-up. Adjusting linear models for age, sex, and ADRD pathologies, we isolated thirteen proteins that may provide motor resilience (Bonferroni correction p < 5 × 10-6). FME models showed, that on average, progression of parkinsonian signs was non-linear from 25 to 12 years before death, followed by accelerated linear decline until death. Five of thirteen resilience proteins were also related to non-linear decline. Motor resilience may be supported by a coordinated network of proteins that help to preserve neuronal structure, cellular transport, and synaptic integrity, functions critical for diverse aging phenotypes.
conclusionsCortical proteins may provide motor resilience for both linear and non-linear motor decline. Further drug discovery targeting resilience proteins may yield therapies that can reduce motor impairment even in the absence of treatments for ADRD pathologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.